<DOC>
	<DOCNO>NCT00051480</DOCNO>
	<brief_summary>The primary purpose study assess safety feasibility give TNFerade™ 5-FU , Cisplatin radiation therapy patient locally advance , esophageal cancer prior surgical resection . TNFerade™ replication deficient ( E1 , E3 E4 delete ) adenovirus vector contain gene TNF-alpha control radiation inducible promoter . This allow expression TNF-alpha great area receive radiation . TNF-alpha potent cytokine show potent anti-cancer activity , due systemic toxicity , could deliver effective dos . TNFerade™ novel way selective delivery TNF-alpha tumor cell . TNFerade™ deliver week five week direct intratumoral injection use endoscopy Endoscopic Ultrasound . 5-FU ( 1000 mg/m2/day ) deliver via continuous infusion 96 hour week 1 4 . Cisplatin ( 75 mg/m2 ) deliver Day 1 Day 29 intravenously . The dose radiation deliver 45 Gy 1.8 Gy fraction 5 week .</brief_summary>
	<brief_title>Study TNFerade™ Gene Therapy , Radiation , 5-FU Cisplatin Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Inclusion criterion : 1875 year age ; Patients biopsy proven locally advanced adenocarcinoma squamous cell carcinoma esophagus , stage II , III , receive previous treatment consider resectable carcinoma ; Informed consent ; Karnofsky performance status ≥ 70 % ; Life expectancy great 6 month . Exclusion criterion : Diagnosis lymphoma esophagus ; History malignancy past 2 year except carcinoma situ cervix bladder , nonmelanomatous skin cancer localize early stage prostate cancer patient continuously diseasefree ; Previous chemotherapy radiation esophageal cancer previous radiation therapy target field ; T4 disease , metastatic ( stage IV ) disease confirm invasion bronchial tree ; Extension beyond 2 cm stomach ; Liver enzymes &gt; 2.0 x ULN ( ALT , AST , bilirubin , alkaline phosphatase ) ; Coagulopathy ( INR &gt; 1.5 , PTT ratio &gt; 1.5 ) ; Renal insufficiency ( creatinine &gt; 2.0 mg/dL ; calculate creatinine clearance &lt; 50 ml/min ) ; Significant anemia ( hematocrit &lt; 28 % hemoglobin &lt; 9 g/dL ) ( may RBC transfusion ) , thrombocytopenia ( platelet count &lt; 100,000/μL ) l leukopenia ( WBC &lt; 3,000/µL ; ANC &lt; 1,500 μL ) ; Contraindication endoscopic EUSguided delivery include obstructive lesion dilate pas endoscope ; Clinical evidence active infection type , include hepatitis B C virus ; Due embryotoxic effect chemotherapy , pregnant lactate woman , men unable unwilling practice contraception exclude ; Experimental medication within last four week prior Day 1 ; Chronic systemic corticosteriod use ( orally parenterally administer ) ; Significant concurrent medical psychiatric illness define investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>